2026-02-10, 6:36:33 a.m.
AGOURA HILLS, Calif. — February 10, 2026 — Leads & Copy — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) provided an update on key development progress achieved during 2025 and outlined its strategic direction as the Company enters 2026 with continued momentum across its pipeline.
In 2025, Oncotelic transitioned from platform build-out to execution and validation, advancing AI-driven discovery (PDAOAI), moving key assets into the clinic, publishing high-impact translational science, and reinforcing asset value through independent validation. These milestones establish a strong foundation for late-stage development, partnering, and strategic financing.
Key accomplishments from 2025 include the unveiling of PDAOAI, Oncotelic’s proprietary AI-enabled knowledge platform built on a comprehensive TGF-β–centric corpus. The platform was expanded to support interactive querying, biomarker discovery, and translational hypothesis generation, and was publicly introduced alongside peer-reviewed GBM and pancreatic cancer research. PDAOAI now functions as a cross-program decision-support layer integrating molecular biology, clinical outcomes, and regulatory-grade literature.
The company completed a Phase 1 clinical trial of OT-101 in combination with IL-2. In parallel, its IV everolimus Deciparticle™ program (Sapu-003) advanced from preclinical development into first-in-human clinical testing.
Throughout 2025, Oncotelic released data validating the Deciparticle™ platform, demonstrating broad applicability across hydrophobic small-molecule drug classes and reporting favorable PK and tissue-distribution profiles, including reduced gastrointestinal accumulation compared with oral everolimus. A biomarker-guided framework was introduced to identify patient populations most likely to benefit from IV mTOR inhibition. These results position Deciparticle™ as a differentiated delivery technology for oncology and other systemic indications.
Oncotelic and collaborators published multiple peer-reviewed studies in 2025, linking TGFB2 expression and methylation status to survival outcomes in pancreatic cancer, glioblastoma, and liver cancer, including age- and context-dependent effects. Additional work reviewed sub-20 nm nanoparticle design principles, supporting the scientific rationale behind the Deciparticle™ platform.
The company entered a strategic partnership with Medicilon to access rapid IND-enabling capabilities, complementing Oncotelic’s global regulatory strategy.
An independent third-party analysis valued the GMP Bio joint-venture pipeline at approximately $1.7 billion, materially strengthening Oncotelic’s asset-level valuation narrative. The company increased capital-markets visibility through various investor presentations, while continuing disciplined communication around pipeline maturation and platform leverage.
As the Company enters 2026, Oncotelic plans to build on the progress achieved in 2025 with an emphasis on continued development momentum, thoughtful capital allocation, strategic execution, and increased financial transparency. The Company’s forward priorities include advancing clinical programs toward their next inflection points, further evaluating regulatory and development pathways across oncology and CNS indications, exploring partnership, licensing, and collaboration opportunities aligned with its late-stage assets, continuing to strengthen operational readiness to support future growth initiatives, and completing a second independent U.S.-based valuation to support the remeasurement of its 45% equity interest in the GMP Bio joint venture.
Oncotelic believes its steady progress in 2025 has positioned the Company with a clear development trajectory, enhanced asset visibility, and multiple opportunities to unlock long-term value.
“2025 was a year of continued execution and foundation-building for Oncotelic,” said Dr. Vuong Trieu, Chairman and Chief Executive Officer of Oncotelic. “We advanced a diversified pipeline with prior late-stage clinical experience while maintaining focus on areas of significant unmet medical need. As we move into 2026, our team remains fully engaged and energized, with a clear commitment to disciplined development, strategic flexibility, and long-term value creation for patients and shareholders.”
Oncotelic Therapeutics, Inc. is focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the Company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance.
Source: Oncotelic Therapeutics, Inc.
